Aclarion Inc. (NASDAQ: ACON, ACONW) announced the issuance of U.S. Patent #12,601,803 for its machine learning platform that analyzes magnetic resonance spectroscopy data to assess chronic low back pain, according to a company press release.

The patent covers machine learning models that extract biomarkers from MRS spectral data and generate classifications for pain-related conditions. It also protects AI-based automated data quality controls that detect and exclude low-quality signals, including excessive lipids and spectral artifacts.

The Broomfield, Colorado-based healthcare technology company's cloud-based platform, Nociscan, converts MRS spectral data into clinical insights to help physicians distinguish between painful and non-painful spinal discs. The patent is intended to enable the company to automate biomarker identification and accelerate report generation in future platform versions.

"This patent strengthens the foundation of our platform by protecting how we leverage AI to transform complex spectroscopy data into meaningful, actionable information that physicians can integrate into everyday practice," said Brent Ness, Chief Executive Officer of Aclarion.

The new patent expands Aclarion's intellectual property portfolio to 64 issued and pending patents worldwide. The company stated that clinical data has demonstrated up to a 97% surgical success rate when all Nociscan-positive discs are treated alongside other diagnostic tools.

Chronic low back pain affects approximately 266 million people worldwide, according to the company's statement.